Needham & Company LLC Reiterates “Buy” Rating for Generation Bio (NASDAQ:GBIO)

Generation Bio (NASDAQ:GBIO)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $15.00 price objective on the stock. Needham & Company LLC’s target price indicates a potential upside of 174.22% from the stock’s previous close.

A number of other equities analysts have also weighed in on GBIO. Canaccord Genuity Group lifted their price target on shares of Generation Bio from $9.00 to $10.00 and gave the company a “buy” rating in a report on Monday, August 18th. Wall Street Zen lowered Generation Bio from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Generation Bio in a research report on Wednesday, October 8th. Finally, Wedbush lowered Generation Bio from an “outperform” rating to a “neutral” rating and set a $7.00 price target for the company. in a research note on Wednesday, August 13th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Generation Bio presently has an average rating of “Hold” and an average price target of $10.67.

Generation Bio Price Performance

NASDAQ:GBIO traded up $0.36 during mid-day trading on Friday, reaching $5.47. The company’s stock had a trading volume of 100,490 shares, compared to its average volume of 144,516. The stock has a market cap of $36.87 million, a P/E ratio of -0.59 and a beta of 2.51. The company’s fifty day simple moving average is $5.95 and its two-hundred day simple moving average is $4.89. Generation Bio has a twelve month low of $3.00 and a twelve month high of $23.80.

Generation Bio (NASDAQ:GBIO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($3.18) by $2.36. Generation Bio had a negative net margin of 410.13% and a negative return on equity of 94.82%. The company had revenue of $1.59 million during the quarter, compared to the consensus estimate of $0.66 million. Sell-side analysts expect that Generation Bio will post -1.75 EPS for the current fiscal year.

Institutional Trading of Generation Bio

Large investors have recently bought and sold shares of the company. Militia Capital Partners LP purchased a new stake in Generation Bio during the 2nd quarter worth approximately $174,000. Marshall Wace LLP acquired a new stake in shares of Generation Bio during the second quarter worth approximately $37,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Generation Bio during the second quarter worth approximately $47,000. Acadian Asset Management LLC increased its stake in shares of Generation Bio by 54.3% in the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock worth $468,000 after buying an additional 407,843 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in Generation Bio in the first quarter valued at $36,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.